First Fully Personalized mRNA Cancer Vaccine Shows 62% Recurrence Reduction in Phase III Trial
A Phase III trial of Moderna and Merck's personalized mRNA cancer vaccine showed a 62% reduction in melanoma recurrence, with regulatory submissions expected in the U.S. and EU before year-end.